{"Title": "Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington\u2019s disease", "Year": 2018, "Source": "Eur. J. Nucl. Med. Mol. Imaging", "Volume": "45", "Issue": 9, "Art.No": null, "PageStart": 1546, "PageEnd": 1556, "CitedBy": 10, "DOI": "10.1007/s00259-018-4033-0", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85046159935&origin=inward", "Abstract": "\u00a9 2018, Springer-Verlag GmbH Germany, part of Springer Nature.Aim: To evaluate the incremental value of FDG-PET over clinical tests in: (i) diagnosis of amyotrophic lateral sclerosis (ALS); (ii) picking early signs of neurodegeneration in patients with a genetic risk of Huntington\u2019s disease (HD); and detecting metabolic changes related to cognitive impairment in (iii) ALS and (iv) HD patients. Methods: Four comprehensive literature searches were conducted using the PICO model to extract evidence from relevant studies. An expert panel then voted using the Delphi method on these four diagnostic scenarios. Results: The availability of evidence was good for FDG-PET utility to support the diagnosis of ALS, poor for identifying presymptomatic subjects carrying HD mutation who will convert to HD, and lacking for identifying cognitive-related metabolic changes in both ALS and HD. After the Delphi consensual procedure, the panel did not support the clinical use of FDG-PET for any of the four scenarios. Conclusion: Relative to other neurodegenerative diseases, the clinical use of FDG-PET in ALS and HD is still in its infancy. Once validated by disease-control studies, FDG-PET might represent a potentially useful biomarker for ALS diagnosis. FDG-PET is presently not justified as a routine investigation to predict conversion to HD, nor to detect evidence of brain dysfunction justifying cognitive decline in ALS and HD.", "AuthorKeywords": ["Amyotrophic lateral sclerosis", "Behavioral abnormalities", "Cognitive impairment", "FDG-PET", "Huntington\u2019s disease", "Mutation gene carrier"], "IndexKeywords": ["Amyotrophic Lateral Sclerosis", "Brain", "Fluorodeoxyglucose F18", "Humans", "Huntington Disease", "Positron-Emission Tomography", "Radiopharmaceuticals"], "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 2, "EID": "2-s2.0-85046159935", "SubjectAreas": [["Radiology, Nuclear Medicine and Imaging", "MEDI", "2741"]], "AuthorData": {"6701687853": {"Name": "Agosta F.", "AuthorID": "6701687853", "AffiliationID": "60009622, 60082964", "AffiliationName": "Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University"}, "57191225963": {"Name": "Altomare D.", "AuthorID": "57191225963", "AffiliationID": "60015300", "AffiliationName": "Department of Molecular and Translational Medicine, University of Brescia"}, "57194078503": {"Name": "Festari C.", "AuthorID": "57194078503", "AffiliationID": "60015300", "AffiliationName": "Department of Molecular and Translational Medicine, University of Brescia"}, "6507801629": {"Name": "Boccardi M.", "AuthorID": "6507801629", "AffiliationID": "60004718", "AffiliationName": "LANVIE (Laboratoire de Neuroimagerie du Vieillissement), Department of Psychiatry, University of Geneva"}, "6507213223": {"Name": "Orini S.", "AuthorID": "6507213223", "AffiliationID": "60084291", "AffiliationName": "Alzheimer Operative Unit, IRCCS S. Giovanni di Dio, Fatebenefratelli"}, "57201799163": {"Name": "Gandolfo F.", "AuthorID": "57201799163", "AffiliationID": "60084291", "AffiliationName": "Alzheimer Operative Unit, IRCCS S. Giovanni di Dio, Fatebenefratelli"}, "6701781098": {"Name": "Arbizu J.", "AuthorID": "6701781098", "AffiliationID": "60033320", "AffiliationName": "Department of Nuclear Medicine, Clinica Universidad de Navarra, University of Navarra"}, "12806241300": {"Name": "Bouwman F.", "AuthorID": "12806241300", "AffiliationID": "60008734, 60013779, 60001997", "AffiliationName": "Department of Neurology & Alzheimer Center, Amsterdam Neuroscience, VU University Medical Center"}, "6603680777": {"Name": "Drzezga A.", "AuthorID": "6603680777", "AffiliationID": "60008658, 60024025", "AffiliationName": "Department of Nuclear Medicine, University Hospital of Cologne, University of Cologne and German Center for Neurodegenerative Diseases (DZNE)"}, "57189881899": {"Name": "Nestor P.", "AuthorID": "57189881899", "AffiliationID": "60031004, 60028090", "AffiliationName": "Queensland Brain Institute, University of Queensland and at the Mater Hospital Brisbane"}, "57206948479": {"Name": "Nobili F.", "AuthorID": "57206948479", "AffiliationID": "60025153, 60107402", "AffiliationName": "Department of Neuroscience (DINOGMI), University of Genoa and Polyclinic San Martino Hospital"}, "36830984200": {"Name": "Walker Z.", "AuthorID": "36830984200", "AffiliationID": "60171633, 60022148", "AffiliationName": "Division of Psychiatry & Essex Partnership University NHS Foundation Trust, University College London"}, "57197175050": {"Name": "Pagani M.", "AuthorID": "57197175050", "AffiliationID": "60019295", "AffiliationName": "Department of Nuclear Medicine, Karolinska Hospital Stockholm"}, "null": {"Name": null, "AuthorID": null, "AffiliationID": null, "AffiliationName": null}}}